These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23148192)

  • 1. The effects of old, new and emerging medicines on metabolic aberrations in PCOS.
    Bargiota A; Diamanti-Kandarakis E
    Ther Adv Endocrinol Metab; 2012 Feb; 3(1):27-47. PubMed ID: 23148192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women.
    Baldani DP; Skrgatic L; Ougouag R
    Int J Endocrinol; 2015; 2015():786362. PubMed ID: 26124830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
    Sanchez-Garrido MA; Tena-Sempere M
    Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hyperinsulinaemia and insulin resistance on endocrine, metabolic and fertility outcomes in women with polycystic ovary syndrome undergoing ovulation induction.
    Zhang D; Yang X; Li J; Yu J; Wu X
    Clin Endocrinol (Oxf); 2019 Sep; 91(3):440-448. PubMed ID: 31222771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?
    Ruan X; Li M; Mueck AO
    Curr Pharm Des; 2018; 24(39):4685-4692. PubMed ID: 30706800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.
    Barrea L; Marzullo P; Muscogiuri G; Di Somma C; Scacchi M; Orio F; Aimaretti G; Colao A; Savastano S
    Nutr Res Rev; 2018 Dec; 31(2):291-301. PubMed ID: 30033891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
    Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
    Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.
    Abdalla MA; Deshmukh H; Atkin S; Sathyapalan T
    Ther Adv Endocrinol Metab; 2020; 11():2042018820938305. PubMed ID: 32670541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome.
    Morrison SA; Goss AM; Azziz R; Raju DA; Gower BA
    Hum Reprod; 2017 Jan; 32(1):185-192. PubMed ID: 27827322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.
    Teede H; Deeks A; Moran L
    BMC Med; 2010 Jun; 8():41. PubMed ID: 20591140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome.
    Wehr E; Möller R; Horejsi R; Giuliani A; Kopera D; Schweighofer N; Groselj-Strele A; Pieber TR; Obermayer-Pietsch B
    Wien Klin Wochenschr; 2009; 121(7-8):262-9. PubMed ID: 19562283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.
    Ortiz-Flores AE; Luque-Ramírez M; Escobar-Morreale HF
    Expert Opin Pharmacother; 2018 Dec; 19(17):1915-1926. PubMed ID: 30289728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipose insulin resistance is associated with cardiovascular risk factors in polycystic ovary syndrome.
    Mu L; Li R; Lai Y; Zhao Y; Qiao J
    J Endocrinol Invest; 2019 May; 42(5):541-548. PubMed ID: 30206805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment.
    Baldani DP; Skrgatic L; Ougouag R; Kasum M
    Gynecol Endocrinol; 2018 Feb; 34(2):87-91. PubMed ID: 28944709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of polycystic ovary syndrome: a practical guide.
    Stankiewicz M; Norman R
    Drugs; 2006; 66(7):903-12. PubMed ID: 16740005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.